Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L. Dowlati A, et al. Among authors: parkes a. J Clin Oncol. 2024 Oct 10;42(29):3392-3399. doi: 10.1200/JCO.24.00553. Epub 2024 Aug 29. J Clin Oncol. 2024. PMID: 39208379 Free PMC article. Clinical Trial.
Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study.
Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE; theMednet.org NCI-CCC Tumor Board Program Collaborative Group; Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N. Kalra M, et al. Among authors: parkes a. JMIR Cancer. 2022 May 19;8(2):e33859. doi: 10.2196/33859. JMIR Cancer. 2022. PMID: 35588361 Free PMC article.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Kamaraju S, Fowler AM, Tarima S, Chaudhary LN, Burkard ME, Giever T, Cheng YC, Parkes A, Lange CA, Pipp-Dahm M, Hegeman R, Siddiqui N, Stella A, Rajguru S, Twaroski K, Zurbriggen L, Jorns JM, Rui H, Keigley QJ, Perlman SB, Salem K, Bradshaw TJ, Sahmoud T, Wisinski K. Kamaraju S, et al. Among authors: parkes a. Clin Breast Cancer. 2024 Dec 10:S1526-8209(24)00333-1. doi: 10.1016/j.clbc.2024.11.019. Online ahead of print. Clin Breast Cancer. 2024. PMID: 39824712
Lipid-Modulated, Graduated Inhibition of N-Glycosylation Pathway Priming Suggests Wide Tolerance of ER Proteostasis to Stress.
Giltrap AM, Morris N, Dong YY, Cochrane SA, Krulle T, Hoekman S, Semmelroth M, Wollnik C, Palmai-Pallag T, Carpenter EP, Hollick J, Parkes A, Rudhard Y, Davis BG. Giltrap AM, et al. Among authors: parkes a. ACS Cent Sci. 2024 Dec 26;11(1):107-115. doi: 10.1021/acscentsci.4c01506. eCollection 2025 Jan 22. ACS Cent Sci. 2024. PMID: 39866694 Free PMC article.
Identification of a novel nuclease activity in human DDX49 helicase.
Parkes AJ, Anandavijayan S, Lou-Hing A, Downs O, Killelea T, Martin L, Kapllanaj F, Bolt EL. Parkes AJ, et al. R Soc Open Sci. 2024 Dec 18;11(12):241891. doi: 10.1098/rsos.241891. eCollection 2024 Dec. R Soc Open Sci. 2024. PMID: 39698160 Free PMC article.
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study.
Minocha M, Thompson CG, Murphy A, Zhou Y, Brandl C, Parkes A, Chen X, Yu B, Martinez P, Houk BE. Minocha M, et al. Among authors: parkes a. Clin Pharmacokinet. 2024 Dec;63(12):1757-1768. doi: 10.1007/s40262-024-01451-7. Epub 2024 Nov 26. Clin Pharmacokinet. 2024. PMID: 39589690 Clinical Trial.
Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti-Acinetobacter drug development and AMR preparedness.
Dubey V, Farrington N, Harper N, Johnson A, Horner I, Stevenson A, Parkes A, Hoare L, Das S, Hope W. Dubey V, et al. Among authors: parkes a. Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0022224. doi: 10.1128/aac.00222-24. Epub 2024 Aug 27. Antimicrob Agents Chemother. 2024. PMID: 39189767
385 results